Almawash S
Cancers (Basel). 2025; 17(5).
PMID: 40075727
PMC: 11899125.
DOI: 10.3390/cancers17050880.
Cao M, Luan J, Zhai C, Liu H, Zhang Z, Guo N
Oncol Lett. 2025; 29(4):181.
PMID: 39990807
PMC: 11843431.
DOI: 10.3892/ol.2025.14927.
Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M
Onco Targets Ther. 2025; 18:233-262.
PMID: 39989503
PMC: 11846535.
DOI: 10.2147/OTT.S493643.
Kulbay M, Tuli N, Mazza M, Jaffer A, Juntipwong S, Marcotte E
Biomedicines. 2025; 13(1).
PMID: 39857692
PMC: 11762644.
DOI: 10.3390/biomedicines13010108.
Santoso A, Levink I, Pihlak R, Chau I
Curr Oncol. 2025; 32(1).
PMID: 39851940
PMC: 11763487.
DOI: 10.3390/curroncol32010024.
Cytokine expression of soft tissue cells cultured with titanium discs and their respective supernatants in vitro.
Dos Santos Sanches N, Panahipour L, Wang L, Imani A, Marchiolli C, Cervantes L
Clin Oral Investig. 2025; 29(1):62.
PMID: 39809969
PMC: 11732886.
DOI: 10.1007/s00784-024-06123-1.
Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
McIlroy G, Gaskell C, Jackson A, Yafai E, Tasker R, Thomas C
BMC Cancer. 2025; 25(1):56.
PMID: 39789479
PMC: 11720754.
DOI: 10.1186/s12885-024-13383-3.
The anti-tumor effect of the IFNγ/Fas chimera expressed on CT26 tumor cells.
Jeon S, Shin H, Lee H, Lee J, Kim Y
Anim Cells Syst (Seoul). 2025; 29(1):46-56.
PMID: 39777022
PMC: 11703469.
DOI: 10.1080/19768354.2024.2442393.
Co-evolution of glioma and immune microenvironment.
Elguindy M, Young J, Ho W, Lu R
J Immunother Cancer. 2024; 12(12.
PMID: 39631850
PMC: 11624716.
DOI: 10.1136/jitc-2024-009175.
Tumor growth suppression in adoptive T cell therapy via IFN-γ targeting of tumor vascular endothelial cells.
Lin Q, Olkowski C, Choyke P, Sato N
Theranostics. 2024; 14(18):6897-6912.
PMID: 39629126
PMC: 11610145.
DOI: 10.7150/thno.101107.
A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer.
Guanizo A, Luong Q, Jayasekara W, de Geus E, Inampudi C, Xue V
Nat Immunol. 2024; 25(12):2259-2269.
PMID: 39572642
DOI: 10.1038/s41590-024-02014-5.
Genomic instability as a driver and suppressor of anti-tumor immunity.
Requesens M, Foijer F, Nijman H, de Bruyn M
Front Immunol. 2024; 15:1462496.
PMID: 39544936
PMC: 11562473.
DOI: 10.3389/fimmu.2024.1462496.
Long-term prognosis and treatment modalities of hepatic epithelioid hemangioendothelioma: a retrospective study of 228 patients.
Liu X, Yang P, Liu L, Si S, Zhou R, Liu T
BMC Cancer. 2024; 24(1):1285.
PMID: 39415114
PMC: 11481724.
DOI: 10.1186/s12885-024-13053-4.
Site-specific O-GlcNAcylation of progesterone receptor (PR) supports PR attenuation of interferon stimulated genes (ISGs) and tumor growth in breast cancer.
Saunders H, Holloran S, Trinca G, Artigues A, Villar M, Tinoco J
J Biol Chem. 2024; 300(11):107886.
PMID: 39395796
PMC: 11609360.
DOI: 10.1016/j.jbc.2024.107886.
Novel prognostic model of complement and coagulation cascade-related genes correlates with immune environment and drug sensitivity in hepatocellular carcinoma.
Su H, Chen Y, Wang W
Heliyon. 2024; 10(19):e38230.
PMID: 39391504
PMC: 11466567.
DOI: 10.1016/j.heliyon.2024.e38230.
Systems profiling reveals recurrently dysregulated cytokine signaling responses in ER+ breast cancer patients' blood.
Orcutt-Jahns B, Lima Junior J, Lin E, Rockne R, Matache A, Branciamore S
NPJ Syst Biol Appl. 2024; 10(1):118.
PMID: 39389979
PMC: 11467214.
DOI: 10.1038/s41540-024-00447-0.
Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.
De S, Ehrlich M
Genes (Basel). 2024; 15(9).
PMID: 39336785
PMC: 11431212.
DOI: 10.3390/genes15091193.
CD91 and Its Ligand gp96 Confer Cross-Priming Capabilities to Multiple APCs during Immune Responses to Nascent, Emerging Tumors.
Nayak D, Sedlacek A, Cillo A, Watkins S, Binder R
Cancer Immunol Res. 2024; 12(12):1663-1676.
PMID: 39269437
PMC: 11614702.
DOI: 10.1158/2326-6066.CIR-24-0326.
Investigation of pre and postoperative Th1/Th2 cytokine balance and novel cytokines in colorectal cancer patients.
Gulcek E, Aydogdu Y, Emreol U, Bagriacik E, Akyurek N
Clin Exp Med. 2024; 24(1):211.
PMID: 39230623
PMC: 11374814.
DOI: 10.1007/s10238-024-01480-3.
Engineered T cells for Colorectal Cancer.
Rus Bakarurraini N, Kamarudin A, Jamal R, Abu N
Immunotherapy. 2024; 16(14-15):987-998.
PMID: 39229803
PMC: 11485792.
DOI: 10.1080/1750743X.2024.2391733.